Current Issue
May 2025
An Endangered Endeavor?
For hematologic malignancies, cooperative clinical trials are just as important as industry-sponsored trials, but they are struggling to thrive.
Viewpoints
Editor’s Corner
“Ordo ab Chao”: Out of Chaos, Order
Letter to the Editor
Redefining Home, Embracing Resilience: Life as an Immigrant in Medicine
Education
You Make the Call
You Make the Call: Would you rule out porphyria in this patient?
Spotlight
Feature Articles
News
In a Different Vein: News from the Blood Journals
PDMPs May Negatively Affect ED Uptake by People With Sickle Cell Disease
Lenalidomide Maintenance Discontinuation a Viable Option for Some Patients With MM
Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML
Literature Scan
Intensive Factor VIII Prophylaxis May Benefit Patients with Hemophilia, Hypertrophic Synovium
Fixed-Duration Acalabrutinib Combinations Effective for Untreated CLL
Daratumumab-Containing Quadruplet Effective as First-Line in Transplant-Ineligible NDMM, Randomized Trial Finds
ASH Directions
ASH Seeks Recipient Nominations, New Award Names for Honorific Awards
ASH Expands Membership to Advanced Practice Providers, Extends Deadline to May 31
Data Stream
Connect with us:
CURRENT ISSUE
May 2025
